Calliditas Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Renee Aguiar-Lucander

Chief Executive Officer (CEO)

kr18.4m

Compensación total

Porcentaje del salario del CEO	36.6%
Permanencia del CEO	7yrs
Participación del CEO	1.2%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Renee Aguiar-Lucander en comparación con los beneficios de Calliditas Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	kr18m	kr7m	-kr466m
Sep 30 2023	n/a	n/a	-kr451m
Jun 30 2023	n/a	n/a	-kr292m
Mar 31 2023	n/a	n/a	-kr393m
Dec 31 2022	kr13m	kr6m	-kr412m
Sep 30 2022	n/a	n/a	-kr628m
Jun 30 2022	n/a	n/a	-kr608m
Mar 31 2022	n/a	n/a	-kr576m
Dec 31 2021	kr11m	kr5m	-kr500m
Sep 30 2021	n/a	n/a	-kr452m
Jun 30 2021	n/a	n/a	-kr600m
Mar 31 2021	n/a	n/a	-kr501m
Dec 31 2020	kr7m	kr3m	-kr433m
Sep 30 2020	n/a	n/a	-kr286m
Jun 30 2020	n/a	n/a	-kr198m
Mar 31 2020	n/a	n/a	-kr54m
Dec 31 2019	kr4m	kr3m	-kr33m
Sep 30 2019	n/a	n/a	-kr54m
Jun 30 2019	n/a	n/a	-kr35m
Mar 31 2019	n/a	n/a	-kr136m
Dec 31 2018	kr4m	kr2m	-kr132m

Compensación vs. Mercado: La compensación total ($USD1.69M) de Renee está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.42M).

Compensación vs. Ingresos: La compensación de Renee ha aumentado mientras la empresa no es rentable.

CEO

Renee Aguiar-Lucander (61 yo)

7yrs

Permanencia

kr18,367,000

Compensación

Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Renee Aguiar-Lucander	Chief Executive Officer	7yrs	kr18.37m	1.2% SEK 6.6m
Fredrik Johansson	Chief Financial Officer	6.8yrs	sin datos	0.080% SEK 441.2k
Lars Stubberud	Head of Technical Operations	1.3yrs	sin datos	sin datos
Asa Hillsten	Head of IR & Sustainability	1.3yrs	sin datos	sin datos
Brian Gorman	Group General Counsel	1.3yrs	sin datos	sin datos
Sandra Frithiof	Head of Human Resources	4.3yrs	sin datos	sin datos
Ann-Kristin Myde	Head of Clinical Development & VP of Project Management	7.3yrs	sin datos	sin datos
Richard Philipson	Chief Medical Officer	3.8yrs	sin datos	sin datos
Teona Johnson	Head of US Marketing	3.2yrs	sin datos	sin datos
David Ferraro	Head of US Sales	3.2yrs	sin datos	sin datos
Monika Tornsen	President of North America	less than a year	sin datos	sin datos
Christopher Ngai	Vice President of Market Access	no data	sin datos	sin datos

3.2yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CALT se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Diane Parks	Independent Non-Executive Director	5yrs	kr795.00k	0.031% SEK 174.4k
Elmar Schnee	Independent Chairman	5yrs	kr1.74m	0.086% SEK 477.2k
Henrik Stenqvist	Independent Non-Executive Director	2yrs	kr762.00k	0.019% SEK 103.2k
Elisabeth Bjork	Independent Director	2yrs	kr587.00k	sin datos
Jonathan Barratt	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jürgen Floege	Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Lafayette	Member of Scientific Advisory Board	no data	sin datos	sin datos
Brad Rovin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Vladimir Tesar	Member of Scientific Advisory Board	no data	sin datos	sin datos
Hérnan Trimarchi	Member of Scientific Advisory Board	no data	sin datos	sin datos
Hilde Furberg	Independent Non-Executive Director	9.7yrs	kr731.00k	sin datos
Heather Reich	Member of Scientific Advisory Board	no data	sin datos	sin datos

5.0yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de CALT se considera experimentada (4.9 años de antigüedad promedio).

Calliditas Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

Calliditas Therapeutics AB (publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Calliditas Therapeutics AB Announces Executive Appointments

Calliditas Therapeutics AB (Publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces Executive Appointments

Recent updates

Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib

Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO

Calliditas Therapeutics AB Provides Patent Update

Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023

Calliditas Therapeutics AB Announces Full FDA Approval of TARPEYO

Calliditas Therapeutics AB (publ) Receives Notice of Allowance for United States Patent Application Covering TARPEYO

Calliditas Therapeutics AB Announces the Initiation of A Phase 2 Clinical Study to Evaluate Setanaxib in Alport Syndrome

Calliditas Therapeutics AB Presents Additional Data Analyses from NefIgArd Phase 3 Trial at American Society of Nephrology Kidney Week 2023

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

Calliditas Therapeutics AB Presents Data from the Nefigard Phase 3 Trial At the 17Th International Symposium on Iga Nephropathy (Iigann) Tokyo 2023

STADA and Calliditas Therapeutics AB Announce Submission of Request to EMA for CHMP to Convert Conditional Marketing Authorization for Kinpeygo to Standard, or Full, Marketing Authorization

Calliditas Therapeutics AB (publ) to Report Q1, 2024 Results on May 16, 2024

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon®? for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (publ) announces that FDA Grants Priority Review for Full Approval of Tarpeyo for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (Publ) Provides Sales Guidance for Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Announces Supportive Interim Data from Phase 2 Head and Neck Cancer Trial with Lead Nox Inhibitor Candidate, Setanaxib

Calliditas Therapeutics AB Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO

Calliditas Therapeutics AB (publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Provides Earnings Outlook for the Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Nine Months, 2023 Results on Nov 16, 2023

Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Calliditas' Partner Everest Medicine's New Drug Application for Nefecon Is Accepted by the China Nmpa

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Calliditas Therapeutics AB (publ) Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Q1, 2023 Results on May 17, 2023

Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M

Calliditas Therapeutics AB (publ) Announces European Commission Approves Kinpeygo® for Adults with Primary IgA Nephropathy

Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy

Calliditas Therapeutics AB Announces Executive Appointments

Calliditas Therapeutics AB (Publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces First Patient Randomized in Phase 2 Trial in Head and Neck Cancer

Calliditas Therapeutics AB Launches an Online Patient Platform

Calliditas Therapeutics AB (publ) Updates First Patient Randomized in Pivotal TRANSFORM Study with Setanaxib

FdA Grants Calliditas Therapeutics Accelerated Approval of Tarpeyo™ (Budesonide) to Reduce Proteinuria in Iga Nephropathy

U.S. Food and Drug Administration Extends Calliditas Therapeutics AB (Publ)'s the PDUFA Goal Date for New Drug Application

Calliditas Therapeutics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 324 million.

Calliditas Therapeutics AB Receives FDA Fast Track Designation for setanaxib in PBC

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency

Calliditas submits nefecon marketing authorisation application to the EMA

U.S. Food and Drug Administration Grants Priority Review for Nefecon of Calliditas Therapeutics AB, for Patients with IgA Nephropathy

Calliditas shares rise 10% as FDA grants priority review for Nefecon

Calliditas Therapeutics AB (publ) Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

Calliditas Therapeutics AB (Publ) Announces Executive Appointments

Calliditas Therapeutics AB (publ) to Report Fiscal Year 2020 Final Results on Apr 27, 2021

Calliditas Therapeutics AB (Publ) Announces That the First Patient Has Been Dosed in the Global Open-Label Extension of the Phase 3 Nefigard Study

Calliditas Therapeutics AB Announces Full Enrollment of the Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces Clinical Development Plan for Setanaxib

Calliditas Therapeutics AB (publ), Annual General Meeting, May 27, 2021

Calliditas Therapeutics AB (publ) to Report First Half, 2021 Results on Aug 19, 2021

Calliditas Therapeutics reports Q3 results

Calliditas Therapeutics AB (publ) Reports Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces the Last Visit of the 200Th Patient Has Taken Place in Part A of the Pivotal NeflgArd Phase 3 Study

Calliditas Therapeutics AB (publ) (OM:CALTX) made a tender offer to acquire 37.3% stake in Genkyotex SA (ENXTPA:GKTX) for €12.1 million.

Calliditas Therapeutics AB (publ) to Report Q1, 2021 Results on May 13, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta